Drugs / XLCART001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03598179 | Jun 2018 → Dec 2019 | B-cell non-Hodgkin lymphoma, lymphoid leukemia | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XLCART001 | “A Single-center, Open Study Evaluating Efficacy and Safety of XLCART001（CD-19） Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects” NCT03598179 ↗ |
| Target | CD19 | “XLCART001（CD-19） Treatment” NCT03598179 ↗ |